We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.80 | 1.63% | 50.03 | 50.03 | 50.20 | 50.37 | 48.85 | 49.17 | 1,363,472 | 00:58:44 |
From May 2019 to May 2024
By Marc Bisbal Arias
Sanofi SA (SAN.FR) said late Tuesday that it has brought a patent-infringement suit against Mylan NV (MYL) in a U.S. court over the French company's disposable insulin pen and vial-drug products for diabetes.
The pharmaceutical said that the suit it filed in the U.S. District Court for the District of New Jersey alleges that Mylan infringed 18 of its patents.
Sanofi said it filed the motion after receiving notification from the American company in mid-September stating that it had submitted a new drug application to the U.S. Food and Drug Administration for an insulin glargine pre-filled pen and vial-drug products.
The company said that the new drug application challenges its patents for Lantus and Lantus SoloSTAR products.
Write to Marc Bisbal Arias at marc.bisbalarias@dowjones.com
(END) Dow Jones Newswires
October 25, 2017 04:44 ET (08:44 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
